Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies

European Heart Journal

Volumn 34, Issue 13, 2013, Pages 972-981

  Shah, Sonia ^a   Casas, Juan P ^a,b   Gaunt, Tom R ^c   Cooper, Jackie ^a   Drenos, Fotios ^a   Zabaneh, Delilah ^a   Swerdlow, Daniel I ^a   Shah, Tina ^a   Sofat, Reecha ^a   Palmen, Jutta ^a   Kumari, Meena ^a   Kivimaki, Mika ^a   Ebrahim, Shah ^b   Smith, George Davey ^c   Lawlor, Debbie A ^c   Talmud, Philippa J ^a   Whittaker, John ^b,d   Day, Ian N M ^c   Hingorani, Aroon D ^a   Humphries, Steve E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Framingham; Lipid genetic score; Lipid medication

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FEMALE; FRAMINGHAM RISK SCORE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 84875980873     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs243     Document Type: Article

References (24)

1. Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
2. Emberson JR, Whincup PH, Morris RW, Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 2003;24: 1719-1726. (Pubitemid 37236860)
3. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002;324:1570-1576. (Pubitemid 34713139)
4. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
5. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-298.
6. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
7. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9-13. (Pubitemid 29336425)
8. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002;105:310-315. (Pubitemid 34106178)
9. Krauss RM. What can the genome tell us about LDL cholesterol? Lancet 2008; 371:450-452. (Pubitemid 351199871)
10. Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Gen 2009;85:628-642.
11. Marmot M, Brunner E. Cohort Profile: the Whitehall II study. Int Journal Epidemiol 2005;34:251-256.
12. Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003;57:134-140. (Pubitemid 36160623)
13. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PloS One 2008;3:e3583.
14. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55: 997-1004.
15. Sabia S, Kivimaki M, Kumari M, Shipley MJ, Singh-Manoux A. Effect of Apolipoprotein E epsilon4 on the association between health behaviours and cognitive function in late midlife. Mol Neurodegener 2010;1:23.
16. Abdollahi MR, Guthrie PAI, Smith GD, Lawlor DA, Ebrahim S, Day INM. Integrated single-label liquid-phase assay of APOE codons 112 and 158 and a lipoprotein study in British women. Clin Chem 2006;52:1420-1423. (Pubitemid 43956036)
17. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974;19:716-723.
18. Bennet AM, Di Angelantonio E, Ye Z,Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-1311. (Pubitemid 47443344)
19. Murray A, Cluett C, Bandinelli S, Corsi AM, Ferrucci L, Guralnik J, Singleton A, Frayling T, Melzer D. Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people. Eur Heart J 2009;30:1711-1719.
20. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki M, Nieminen MS, Melander O, Salomma V, Peltonen L, Kathiresan S. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 2010;376: 1393-1400.
21. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M. Polymorphisms associated with cholesterol and risk of cardiovascular events. NEJM 2008;358:1240-1249. (Pubitemid 351439225)
22. Davies NM, Windmeijer F, Martin RM, Abdollahi MR, Davey Smith G, Lawlor DA, Ebrahim S, Day IN. Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle. Clin Chem 2011;57:502-510.
23. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-713.
24. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AR, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore A, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TFC, McCarroll SA, Visscher PM. Finding the missing heritability of complex diseases. Nature 2009;461:747-753.